Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-07-2013 | Editorial Commentary

Optimisation and harmonisation: two sides of the same coin?

Author: Ronald Boellaard

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2013

Excerpt

¹⁸F-Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) examinations are executed for several oncological applications [1]. In most cases PET/CT studies are performed with a diagnostic intent, often interpreted using visual inspection of the images. The primary task of the observer is e.g. to identify unknown primary tumours, lymph node involvement and the assessment of distant metastasis. It has been shown that FDG PET/CT is an important tool for either up or down staging of lung cancer patients with a direct impact on patient management [2]. The uptake of FDG can be used as a prognostic factor both in the clinical setting and in trials [3]. In addition to diagnosis and staging, FDG PET/CT is used to measure treatment response. Here residual FDG uptake or changes in uptake during or after treatment are used as predictive factors [4‐6]. To this end, criteria to measure FDG uptake changes and/or metabolic response have been proposed [7, 8]. Finally, PET/CT studies performed at follow-up are used to assess presence or absence of recurrence of disease. Apart from the various applications of FDG PET/CT listed above, there are many other utilities of FDG PET/CT. For example, it can be used for radiation oncology purposes [9‐12], e.g. by identifying areas with high metabolic activity that may require a boost of radiation to improve treatment outcome. …

Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008;49(3):480–508.PubMedCrossRef

Czernin J, len-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 2007;48 Suppl 1:78S–88.

Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer 2007;110(8):1654–64.PubMedCrossRef

Kobe C, Scheffler M, Holstein A, Zander T, Nogoya L, Lammertsma AA, et al. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging 2012;39(7):1117–27.PubMedCrossRef

Weber WA. PET for response assessment in oncology: radiotherapy and chemotherapy. Br J Radiol 2005;Suppl 28:42–9.CrossRef

Zander T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, Hellmich M, et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol 2011;29(13):1701–8.PubMedCrossRef

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S–50.

Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35(13):1773–82.PubMedCrossRef

Chiti A, Kirienko M, Grégoire V. Clinical use of PET-CT data for radiotherapy planning: what are we looking for? Radiother Oncol 2010;96(3):277–9.PubMedCrossRef

10.

Gregoire V, Chiti A. PET in radiotherapy planning: particularly exquisite test or pending and experimental tool? Radiother Oncol 2010;96(3):275–6.PubMedCrossRef

11.

Roels S, Slagmolen P, Nuyts J, Lee JA, Loeckcx D, Maes F, et al. Biological image-guided radiotherapy in rectal cancer: challenges and pitfalls. Int J Radiat Oncol Biol Phys 2009;75:782–90.PubMedCrossRef

12.

Thorwarth D, Schaefer A. Functional target volume delineation for radiation therapy on the basis of positron emission tomography and the correlation with histopathology. Q J Nucl Med Mol Imaging 2010;54(5):490–9.PubMed

13.

Weber WA. Chaperoning drug development with PET. J Nucl Med 2006;47(5):735–7.PubMed

14.

Karantanis D, Kalkanis D, Allen-Auerbach M, Bogsrud TV, Subramaniam RM, Danielson A, et al. Oncologic 18F-FDG PET/CT: referring physicians’ point of view. J Nucl Med 2012;53(10):1499–505.PubMedCrossRef

15.

Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006;24(20):3282–92.PubMedCrossRef

16.

Andersen FL, Klausen TL, Loft A, Beyer T, Holm S. Clinical evaluation of PET image reconstruction using a spatial resolution model. Eur J Radiol 2013;82(5):862–9.PubMedCrossRef

17.

Lasnon C, Hicks RJ, Beauregard JM, Milner A, Paciencia M, Guizard AV, et al. Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer. Clin Nucl Med 2012;37(10):971–6.PubMedCrossRef

18.

Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37(1):181–200.PubMedCrossRef

19.

Boellaard R. Need for standardization of 18F-FDG PET/CT for treatment response assessments. J Nucl Med 2011;52 Suppl 2:93S–100.

20.

Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med 2009;50 Suppl 1:11S–20.

21.

Beyer T, Czernin J, Freudenberg LS. Variations in clinical PET/CT operations: results of an international survey of active PET/CT users. J Nucl Med 2011;52:303–10.PubMedCrossRef

22.

Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging 2013. doi:10.1007/s00259-013-2391-1.PubMed

23.

Cheebsumon P, Yaqub M, van Velden FH, Hoekstra OS, Lammertsma AA, Boellaard R. Impact of [(18)F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology. Eur J Nucl Med Mol Imaging 2011;38(12):2136–44.PubMedCrossRef

24.

Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004;45(9):1519–27.PubMed

25.

Lodge MA, Chaudhry MA, Wahl RL. Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med 2012;53(7):1041–7.PubMedCrossRef

Title: Optimisation and harmonisation: two sides of the same coin?
Author: Ronald Boellaard
Publication date: 01-07-2013
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2440-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Optimisation and harmonisation: two sides of the same coin?

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2013

Reply to comment by Treglia and Bertagna: FDG PET/CT for detection of infectious endocarditis

Influence of selected b values on ADC quantification in diffusion-weighted MRI. Comment on Punwani et al.: Diffusion-weighted MRI of lymphoma: prognostic utility and implications for PET/MRI?

Congenital isolated H-type tracheo-oesophageal fistula identified by milk scan

Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine

Myocardial perfusion imaging and coronary calcium scoring with a two-slice SPECT/CT system: can the attenuation map be calculated from the calcium scoring CT scan?

18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT